Surface Transforms management deliver positive operational update 16.09.2019 Watch Now

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price: 0.34
Bid: 0.33
Ask: 0.35
Change: 0.005 (1.49%)
Spread: 0.02 (6.06%)
Open: 0.335
High: 0.34
Low: 0.335
Yest. Close: 0.335
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

Mon, 3rd Jun 2019 17:38

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint kinase 1 inhibitor.

Meanwhile, positive preliminary clinical data from two first-in-human phase 1/2 studies of SRA737, as monotherapy and as low dose gemcitabine, were presented on Saturday last week.

The two phase 1/2 signal-seeking clinical trials were successful in establishing safety and proof-of-concept activity in multiple cancer indications, such as identifying genetic contexts that sensitise tumours to SRA737, Sareum said.

Also, a "very promising" signal was observed in anogenital cancer, which represents a tractable opportunity to potentially pursue trials leading to market registration filings given its unmet medical need.

Looking forward, Sierra said it intends to evaluate further the clinical data in the context of its emerging pipeline, noting that a phase 2 registration trial for SRA737+LDG in anogenital cancer would cost an estimated USD10 million.

"It seems clear that, with proof-of-concept established, there are multiple opportunities for the ongoing development of this exciting prospect, particularly in combination with other therapeutic approaches," said Sareum Chief Executive Tim Mitchell.

"The success of the trials and the exciting future development opportunities discussed increases the likelihood of further milestone payments being received and we look forward to further development updates in due course," Mitchell added.

Sareum shares closed 4.2% higher on Monday at 0.62 pence each.

More News

Sareum Optimistic On Cancer Treatment As Partner Changes Focus

(Alliance News) - Small molecule drug developer Sareum Holdings PLC on Tuesday said investee Sierra Oncology will need to look at new options to progress development of a key drug.Sierra to

27 Aug 19 13:24

Sareum Holdings expects broadly flat interim losses

(Sharecast News) - Drug developer Sareum expects interim losses to be broadly flat year-on-year as it continues to focus on the development of multiple treatments for cancer and autoimmune diseases.

27 Aug 19 08:35

Sareum Raises GBP513,000 Through Discounted Placing For Pipeline Push

(Alliance News) - Sareum Holdings PLC said Tuesday it raised GBP513,000 through a discounted share placing by Hybridan LLP, whilst also opening the offer to retail investors through drug firm at ,

25 Jun 19 18:33

Sareum Plans To Start Human Trials Of Two Drug Candidates In 2020

(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in

13 Jun 19 15:49

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint

3 Jun 19 17:38

Sareum Reports Positive Data From Trials Of SRA737 In Advanced Cancer

LONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a

3 Jun 19 10:02

Sareum Interim Loss Deepens On Costs As Pipeline Continues Progress

LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to

4 Mar 19 10:58

Sareum's loss widens as development costs expand

(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.

4 Mar 19 08:26

Sareum flags potentially significant findings for SRA737

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.

28 Feb 19 14:33

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to

11 Dec 18 15:55

Sareum Reports Efficacy Data For Immunotherapy Combination With SRA737

LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the

30 Nov 18 11:48

Sareum Holdings Raises GBP850,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug

26 Oct 18 09:20

Sareum raises £850,000 to fund cancer inhibitor

(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.

26 Oct 18 08:38

Sareum Swings To Annual Loss After Prior Year Profit From Associates

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at

1 Oct 18 11:30

Sareum Holdings selects cancer therapy development candidate

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.

26 Sep 18 15:20

Login to your account

Don't have an account? Click here to register.